October 18, 2018 Source: drugdu 116
GW Pharmaceutical’s Epidiolex, the cannabidiol CBD that received a green light from the FDA for management of rare variants of epilepsy, is determined to change physicians’ perspectives about it and make it stand out from the oils available at cannabis stores and hence, recruited around 66 sales executives related to neurology dedicated to persuading 5,000 specialists who treat epilepsy in the U.S.
“We’re the leader in this area, we’re science-based, and we believe physicians and patients will desire medicines that have gone through the FDA review process. When a drug is prescribed that’s FDA approved, you know it’s exactly the same every time it’s prescribed and every time it’s taken,” said Stephen Schultz, VP of investor relations at GW.
In addition to the approval, GW was also granted with the change of class for Epidiolex from a Schedule I drug to a Schedule V which labels it under drugs that have the minimum addictive property like Robitussin AC and Pfizer's Lyrica. This rescheduling brought in glad tidings for GW.
The company has designed two specific websites specially designated to the marketing of the drug. One targets physicians and the other is intended to target patients. This will give a boost to the launch of the drug, while Schultz described the marketing as a “medically oriented education commercialization effort” towards doctors.By editor
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.